We have proven that either systemically or topically applied Hsp90 inhibitors belonging to the geldanamycin derivatives (i.e., 17-DMAG or 17AAG) or short peptide derivative TCBL-145 ameliorated disease activity in experimental mouse models of EBA. This evidence concerns the gene HSP90AA1 and acquired epidermolysis bullosa.